Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: recent updates on clinical and imaging features …
Recent advancements in Alzheimer's disease treatment have focused on the elimination of
amyloid-beta (Aβ) plaque, a hallmark of the disease. Monoclonal antibodies such as …
amyloid-beta (Aβ) plaque, a hallmark of the disease. Monoclonal antibodies such as …
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
DA Loeffler - Journal of Alzheimer's Disease, 2024 - content.iospress.com
Amyloid protein-β (Aβ) concentrations are increased in the brain in both early onset and late
onset Alzheimer's disease (AD). In early onset AD, cerebral Aβ production is increased and …
onset Alzheimer's disease (AD). In early onset AD, cerebral Aβ production is increased and …
Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure capability …
JC Michaelian, CC Rowe, SE Kurrle, CD Pond… - medRxiv, 2024 - medrxiv.org
Background: New amyloid-targeting monoclonal antibody (mAb) therapies for Alzheimer's
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
Amyloid related imaging abnormalities in the emergency setting
J Czerminski, S Khatri, B Rao - Emergency Radiology, 2024 - Springer
Since the 2021 FDA approval of the first monoclonal antibody (MAB) therapy for Alzheimer's
disease (AD), treatment has progressed from symptom management to targeting and …
disease (AD), treatment has progressed from symptom management to targeting and …
[PDF][PDF] Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure …
CD Pond, M Woodward, SL Naismith, JC Michaelian… - medrxiv.org
Background: New amyloid-targeting monoclonal antibody (mAb) therapies for Alzheimer's
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …
disease (AD) are currently under review by the Therapeutic Goods Administration for use in …